Live Breaking News & Updates on 0 Mg Or Placebo Over 24 Weeks Patients Will Have Early Stage

A longitudinal dataset indicating the utility of plasma pTau for patient selection in clinical trials of patients with mild Alzheimer's Disease (AD) and the likely therapeutic benefit of oral Xanamem in this population SYDNEY, March 30, 2023 /PRNewswire/ Actinogen Medical ASX: ACW ("ACW" or "the Company")is pleased to announce that its Chief Medical Officer, Dr Dana Hilt will make an oral presentation to the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (ADPD2023)later today in Gothenburg, Sweden. Dr Hilt was invited to present Actinogen's novel Phase 2a data as an oral presentation in a symposium session entitled AD Drug Development Clinical Trials. The presentation details the unique longitudinal dataset demonstrating 1) the utility of using the plasma biomarker pTau181 for selection of patients with a more progressive form of mild AD in clinical trials and 2) an encouraging beneficial effect ....

New South Wales , Vastra Gotalands Lan , Steven Gourlay , Michael Roberts , Ad Drug Development Clinical Trials , International Conference On Alzheimer , Chief Medical Officer , International Conference , Development Clinical , Clinical Dementia Rating Scale , Neurologic Test Battery , A Longitudinal Dataset Indicating The Utility Of Plasma Ptau For Patient Selection In Clinical Trials Patients With Mild Alzheimer 39s Disease Ad And Likely Therapeutic Benefit Oral Xanamem This Population Sydney , March 30 , 023 Prnewswire Actinogen Medical Asx Acw Quot Or The Company Is Pleased To Announce That Its Chief Officer , R Dana Hilt Will Make An Oral Presentation To The International Conference On Alzheimer 39s And Parkinson Diseases Related Neurological Disorders Adpd2023 Later Today In Gothenburg , Weden Dr Hilt Was Invited To Present Actinogen 39s Novel Phase 2a Data As An Oral Presentation Ina Symposium Session Entitled Ad Drug Development Clinical Trials The Details Unique Longitudinal Dataset Demonstrating 1 Utility Of Using Plasma Biomarker Ptau181 For Selection Patients Witha More Progressive Form Mild In And 2 Encouraging Beneficial Effect Xanamem On Endpoints Function Cdr Sb Cognition Ntb These His Analyses Four Studies That Have Shown Positive Results Acw Small Molecule Pave Way 330 Person Xanamia 2b Trial Commence Coming Months Key Points Include Most Anti Amyloid Therapies Failed Recent Lecanemab Shows Onlya Modest , Uggesting The Utility Of Quot Amyloid Hypothesis In Ad Is Limited There Isa Strong Scientific Rationale For Targeted Modulation Brain Cortisol Several Diseases Including And Depression Xanamem Penetrant Small Molecule Inhibitor Tissue Synthesis That Does Not Disturb Normal Homeostasis Regulated By Adrenal Gland Production Four Independent Clinical Studies Have Shown Positive Resultsa Human Pet Study Visualized High Levels Target Engagement Thereby Establishing Suitability Low Doses 5 Mg 10 Daily Investigation Two Randomized , Lacebo Controlled Trials Showed The Same Pattern Of Improved Attention And Working Memory , Oth Key Aspects Of Cognition , N Older , Ognitively Normal Volunteers Analysis Of Biomarker Positive Plasma Ptau181 Patients With Mild Ad Ina Phase 2a Trial Showed Clinically Significant Benefits On Function Cdr Sb And Cognition Ntb Excellent Safety Tolerability Profile In More Than 300 People Treated 1 Clinical Dementia Rating Scale Sum Boxes Neurologic Test Battery The Upcoming Xanamia 2b Will Study 330 Individuals 5 Mg , 0 Mg Or Placebo Over 24 Weeks Patients Will Have Early Stage , Rogressive Ad Defined As Mild Cognitive Impairment Mci Or And Elevated Plasma Ptau181 Key Endpoints Will Bea Composite Based On The Ntb Described In Dr Hilt 39s Presentation Cdr Sb Be Available At Https Actinogen Com Au Corporate Presentations Steven Gourlay , Ctinogen 39s Ceo And Md , Aid Quot Actinogen Is Excited To Present Its Novel Phase 2a Dataset That One Of The First Show Blood Ptau Biomarker Isa Highly Effective Method For Selection Patients Witha Progressive Form Mild Alzheimer 39s Disease Asa Simulation Upcoming 2b Xanamia Trial Data Give Us Confidence In Our Study Design , Ndpoints And Patient Selection Criteria Quot Dr Steven Gourlay Ceo Amp Managing Directorp 61 2 8964 7401e Actinogen Com Au Investors Michael Roberts Investor Relationsm 423 866 231e Announcement Authorised By The Board Of Directors Medical About Acw Is An Asx Listed ,